The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria—CURE Results
Background and Objective: Chronic spontaneous urticaria (CSU) is a distressing disease. We report real-world data from the global Chronic Urticaria Registry (CURE) about associations between various CSU states and sleep impairment, plus important health-related quality-of-life (HRQoL) outcomes and c...
Saved in:
Main Author: | |
---|---|
Other Authors: | |
Format: | Article |
Published: |
2023
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/82431 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
id |
th-mahidol.82431 |
---|---|
record_format |
dspace |
spelling |
th-mahidol.824312023-05-19T15:24:56Z The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria—CURE Results Kolkhir P. Mahidol University Medicine Background and Objective: Chronic spontaneous urticaria (CSU) is a distressing disease. We report real-world data from the global Chronic Urticaria Registry (CURE) about associations between various CSU states and sleep impairment, plus important health-related quality-of-life (HRQoL) outcomes and compared different methods to assess CSU states. Methods: CURE data were collected at baseline and 6-monthly follow-ups (FU). Assessments included CSU states using the Urticaria Control Test (UCT), weekly Urticaria Activity Score (UAS7), and Physician Global Assessment (PhyGA) of treatment response. Complete response to treatment (CR, UAS7 = 0), complete control of disease (CC, UCT = 16), and PhyGA = CR were assessed, plus the Dermatology Life Quality Index and the Chronic Urticaria Quality-of-Life Questionnaire (CU-Q2oL) sleep domain. Results: Overall, 2078 patients were included. At baseline, 9.8%, 17.9%, and 42.3% of patients had UCT = 16, UAS7 = 0, or PhyGA = CR, respectively, which increased at FU1 and FU2. Patients with higher UCT scores had better sleep and HRQoL. The presence of angioedema without wheals, episodic disease, omalizumab treatment, and male sex were associated with CC (P <.05). Among 469 patients who achieved CC or CR, 16.4% (n = 77) showed CC or CR with all 3 instruments. Agreement between UCT = 16 and UAS7 = 0 measurements was moderate (κ = 0.581), but poor between UCT = 16 and PhyGA = CR (κ = 0.208). Conclusions: Few patients had CR/CC of their CSU at baseline entry. Disease control strongly related to good sleep and better HRQoL; therefore, it is important to aim for CR in CSU treatment. Patient-reported UCT and UAS7 assessments demonstrated a more accurate measurement of CSU state versus physician assessments. 2023-05-19T08:24:56Z 2023-05-19T08:24:56Z 2023-02-01 Article Journal of Allergy and Clinical Immunology: In Practice Vol.11 No.2 (2023) , 610-620.e5 10.1016/j.jaip.2022.11.016 22132198 36481420 2-s2.0-85146473423 https://repository.li.mahidol.ac.th/handle/123456789/82431 SCOPUS |
institution |
Mahidol University |
building |
Mahidol University Library |
continent |
Asia |
country |
Thailand Thailand |
content_provider |
Mahidol University Library |
collection |
Mahidol University Institutional Repository |
topic |
Medicine |
spellingShingle |
Medicine Kolkhir P. The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria—CURE Results |
description |
Background and Objective: Chronic spontaneous urticaria (CSU) is a distressing disease. We report real-world data from the global Chronic Urticaria Registry (CURE) about associations between various CSU states and sleep impairment, plus important health-related quality-of-life (HRQoL) outcomes and compared different methods to assess CSU states. Methods: CURE data were collected at baseline and 6-monthly follow-ups (FU). Assessments included CSU states using the Urticaria Control Test (UCT), weekly Urticaria Activity Score (UAS7), and Physician Global Assessment (PhyGA) of treatment response. Complete response to treatment (CR, UAS7 = 0), complete control of disease (CC, UCT = 16), and PhyGA = CR were assessed, plus the Dermatology Life Quality Index and the Chronic Urticaria Quality-of-Life Questionnaire (CU-Q2oL) sleep domain. Results: Overall, 2078 patients were included. At baseline, 9.8%, 17.9%, and 42.3% of patients had UCT = 16, UAS7 = 0, or PhyGA = CR, respectively, which increased at FU1 and FU2. Patients with higher UCT scores had better sleep and HRQoL. The presence of angioedema without wheals, episodic disease, omalizumab treatment, and male sex were associated with CC (P <.05). Among 469 patients who achieved CC or CR, 16.4% (n = 77) showed CC or CR with all 3 instruments. Agreement between UCT = 16 and UAS7 = 0 measurements was moderate (κ = 0.581), but poor between UCT = 16 and PhyGA = CR (κ = 0.208). Conclusions: Few patients had CR/CC of their CSU at baseline entry. Disease control strongly related to good sleep and better HRQoL; therefore, it is important to aim for CR in CSU treatment. Patient-reported UCT and UAS7 assessments demonstrated a more accurate measurement of CSU state versus physician assessments. |
author2 |
Mahidol University |
author_facet |
Mahidol University Kolkhir P. |
format |
Article |
author |
Kolkhir P. |
author_sort |
Kolkhir P. |
title |
The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria—CURE Results |
title_short |
The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria—CURE Results |
title_full |
The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria—CURE Results |
title_fullStr |
The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria—CURE Results |
title_full_unstemmed |
The Benefit of Complete Response to Treatment in Patients With Chronic Spontaneous Urticaria—CURE Results |
title_sort |
benefit of complete response to treatment in patients with chronic spontaneous urticaria—cure results |
publishDate |
2023 |
url |
https://repository.li.mahidol.ac.th/handle/123456789/82431 |
_version_ |
1781415363257303040 |